Mesenchymal stromal cell secretome for traumatic brain injury: Focus on immunomodulatory action

Pischiutta, Francesca; Caruso, Enrico; Cavaleiro, Helena; Salgado, António J.; Loane, David J.; Zanier, Elisa R.

doi:10.1016/j.expneurol.2022.114199

Cited by 21 publications

(15 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…method. [158][159][160] Recently, most pieces of evidence show that the miR-NAs derived from MSC-EVs have a therapeutic effect on TBI treatment. However, the beneficial effects of MSC-derived EVs for TBI treatment and the pathophysiological implications underlying their tremendous therapeutic potential remain unachievable.…”

Section: Traumatic Brain Injurymentioning

confidence: 99%

“…Various studies are currently examining the impact and use of mesenchymal stem cells (MSCs) as a cell‐based therapeutic option for TBI treatment. While this method may be effective, it is believed that there are specific concerns related to invasive procedures, possible immune rejection of the allograft, and tumorigenesis in the context of using MSCs as a possible treatment method 158–160 . Recently, most pieces of evidence show that the miRNAs derived from MSC‐EVs have a therapeutic effect on TBI treatment.…”

Section: Microrna Overexpressing Mscs In Sudden Onset Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

The microRNAs (miRs) overexpressing mesenchymal stem cells (MSCs) therapy in neurological disorders; hope or hype

Shelash Al‐Hawary,

Yahya Ali,

Mustafa

et al. 2023

Biotechnology Progress

View full text Add to dashboard Cite

Altered expression of multiple miRNAs was found to be extensively involved in the pathogenesis of different neurological disorders including Alzheimer's disease, Parkinson's disease, stroke, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. One of the biggest concerns within gene‐based therapy is the delivery of the therapeutic microRNAs to the intended place, which is obligated to surpass the biological barriers without undergoing degradation in the bloodstream or renal excretion. Hence, the delivery of modified and unmodified miRNA molecules using excellent vehicles is required. In this light, mesenchymal stem cells (MSCs) have attracted increasing attention. The MSCs can be genetically modified to express or overexpress a particular microRNA aimed with promote neurogenesis and neuroprotection. The current review has focused on the therapeutic capabilities of microRNAs‐overexpressing MSCs to ameliorate functional deficits in neurological conditions.

show abstract

Section: Traumatic Brain Injurymentioning

confidence: 99%

Section: Microrna Overexpressing Mscs In Sudden Onset Diseasesmentioning

confidence: 99%

The microRNAs (miRs) overexpressing mesenchymal stem cells (MSCs) therapy in neurological disorders; hope or hype

Shelash Al‐Hawary,

Yahya Ali,

Mustafa

et al. 2023

Biotechnology Progress

View full text Add to dashboard Cite

show abstract

“…Cell free therapy, an emerging therapy that is expected to replace cell therapy, has attracted a large number of researchers’ attention ( Dutta et al, 2021 ; Pischiutta et al, 2022 ). The so-called cell-free therapy is the treatment of various diseases with products secreted by cells (also known as extracellular vesicles) ( Han et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of extracellular vesicles of different cell origins in traumatic brain injury: A systematic review and network meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundThere was still no effective treatment for traumatic brain injury (TBI). Recently, many preclinical studies had shown promising efficacy of extracellular vesicles (EVs) from various cell sources. Our aim was to compare which cell-derived EVs were most effective in treating TBI through a network meta-analysis.MethodsWe searched four databases and screened various cell-derived EVs for use in preclinical studies of TBI treatment. A systematic review and network meta-analysis were conducted for two outcome indicators, modified Neurological Severity Score (mNSS) and Morris Water Maze (MWM), and they were ranked by the surface under the cumulative ranking curves (SUCRA). Bias risk assessment was performed with SYRCLE. R software (version 4.1.3, Boston, MA, USA) was used for data analysis.ResultsA total of 20 studies were included in this study, involving 383 animals. Astrocyte-derived extracellular vesicles (AEVs) ranked first in response to mNSS at day 1 (SUCRA: 0.26%), day 3 (SUCRA: 16.32%), and day 7 (SUCRA: 9.64%) post-TBI. Extracellular vesicles derived from mesenchymal stem cells (MSCEVs) were most effective in mNSS assessment on day 14 (SUCRA: 21.94%) and day 28 (SUCRA: 6.26%), as well as MWM’s escape latency (SUCRA: 6.16%) and time spent in the target quadrant (SUCRA: 86.52%). The result of mNSS analysis on day 21 showed that neural stem cell-derived extracellular vesicles (NSCEVs) had the best curative effect (SUCRA: 6.76%).ConclusionAEVs may be the best choice to improve early mNSS recovery after TBI. The efficacy of MSCEVs may be the best in the late mNSS and MWM after TBI.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023377350.

show abstract

“…Exosomes are endosomal membrane-derived vesicles, approximately 50–150 nm in size, formed during endocytosis and secreted by almost all types of cells, and are present in large numbers in body fluids such as blood, urine, cerebrospinal fluid, tears, and saliva. Their main constituents are lipids, proteins, and nucleic acids, including microRNAs (miRNAs), messenger RNA (mRNA), and DNA derived from secretory cells transferred to other cells [ 12 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 ,…”

Section: Introductionmentioning

confidence: 99%

Regulation of Extracellular Vesicle-Mediated Immune Responses against Antigen-Specific Presentation

Matsuzaka

Yashiro

2022

Vaccines

View full text Add to dashboard Cite

Extracellular vesicles (EVs) produced by various immune cells, including B and T cells, macrophages, dendritic cells (DCs), natural killer (NK) cells, and mast cells, mediate intercellular communication and have attracted much attention owing to the novel delivery system of molecules in vivo. DCs are among the most active exosome-secreting cells of the immune system. EVs produced by cancer cells contain cancer antigens; therefore, the development of vaccine therapy that does not require the identification of cancer antigens using cancer-cell-derived EVs may have significant clinical implications. In this review, we summarise the molecular mechanisms underlying EV-based immune responses and their therapeutic effects on tumour vaccination.

show abstract

Mesenchymal stromal cell secretome for traumatic brain injury: Focus on immunomodulatory action

Cited by 21 publications

References 143 publications

The microRNAs (miRs) overexpressing mesenchymal stem cells (MSCs) therapy in neurological disorders; hope or hype

The microRNAs (miRs) overexpressing mesenchymal stem cells (MSCs) therapy in neurological disorders; hope or hype

Efficacy of extracellular vesicles of different cell origins in traumatic brain injury: A systematic review and network meta-analysis

Regulation of Extracellular Vesicle-Mediated Immune Responses against Antigen-Specific Presentation

Contact Info

Product

Resources

About